XPO1 and Miyoshi myopathy: Interestingly, in the bortezomib arm, PI-refractory patients showed an ORR of 43%, confirming preclinical data[52,55] that inhibition of XPO1 might re-sensitize MM cells to proteasome inhibition[57].